Skip to main content
. 2015 Oct 2;6(31):31569–31592. doi: 10.18632/oncotarget.5035

Figure 3. Summary information of differentially expressed genes in c-Myc lung cancer and validation of candidate genes by RT-PCR and Western blotting.

Figure 3

A. Differentially expressed genes in lung adenocarcinomas of c-Myc-transgenic mice: known responsiveness/interaction with c-Myc; proportion (%) of genes containing potential c-Myc binding sites in the promoter region. Left panel: results for 162 up-regulated genes; Right panel: results for 301 down-regulated genes. 1 - known c-Myc targets and their relatives. 2 - known c-Myc targets and their relatives containing c-Myc binding sites. 3 - known c-Myc-responsive genes and their relatives containing c-Myc binding sites. 4 - known c-Myc-responsive genes and relatives. 5 - new c-Myc-responsive genes with predicted and experimentally proven c-Myc binding sites. 6 - new c-Myc-responsive genes. B. RT-PCRs for selected genes: lanes 1–4: control lung; lanes 5–7: pools of small-sized tumors; lanes 8–12: middle-sized tumors; lanes 13–15: large-size tumors. C. Western blot analysis for selected genes: C1–C3 - control non-transgenic lung; T1–T3 - papillary lung adenocarcinomas of SPC/c-Myc-transgenic mice. D. Densitometric scans of Western blots; bars marked with a * are significantly different from non-transgenic animals; p < 0.05.